Director Jesper Hoeiland receives 25,000-share grant at Allarity (ALLR)

Rhea-AI Filing Summary

Allarity Therapeutics director Jesper Hoeiland was granted equity compensation. The Form 4 reports an acquisition of 25,000 shares of Common Stock at a stated price of $0.00 per share, bringing his direct holdings to 25,000 shares after the transaction.

According to a footnote, these shares reflect restricted stock units granted pursuant to Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan, which vested in full on the grant date. This filing reflects a compensation-related award rather than an open-market trade.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hoeiland Jesper

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	25,000	$0.00	--

Holdings After Transaction: Common Stock — 25,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Equity award size: 25,000 shares Reported price per share: $0.00 per share Post-transaction holdings: 25,000 shares

3 metrics

Equity award size 25,000 shares Common Stock granted to director Jesper Hoeiland

Reported price per share $0.00 per share Stated transaction price for the grant

Post-transaction holdings 25,000 shares Total Common Stock directly owned after grant

Key Terms

restricted stock units, Amended and Restated 2021 Equity Incentive Plan, Grant, award, or other acquisition

3 terms

restricted stock units financial

"The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Amended and Restated 2021 Equity Incentive Plan financial

"granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan..."

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoeiland Jesper

(Last) (First) (Middle)

C/O ALLARITY THERAPEUTICS, INC.

123 E TARPON AVE

(Street)

TARPON SPRINGS FLORIDA 34689

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Allarity Therapeutics, Inc. [ ALLR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/07/2026		A		25,000(1)	A	$0	25,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, vested in full on the grant date.

	/s/ Jesper Hoeiland	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Allarity Therapeutics (ALLR) disclose about Jesper Hoeiland in this Form 4?

Allarity Therapeutics disclosed that director Jesper Hoeiland acquired 25,000 shares of Common Stock as an equity award, with his direct holdings increasing to 25,000 shares following the transaction, according to the Form 4 insider filing details provided.

How many Allarity Therapeutics (ALLR) shares did Jesper Hoeiland receive?

Jesper Hoeiland received 25,000 shares of Allarity Therapeutics Common Stock. The filing shows this equity was awarded as part of his compensation, with 25,000 shares reported as directly owned after the grant, indicating this was his entire disclosed position post-transaction.

What type of equity award did Allarity Therapeutics (ALLR) grant to Jesper Hoeiland?

The award was in the form of restricted stock units tied to Allarity Therapeutics Common Stock. A footnote explains these RSUs were granted under the Amended and Restated 2021 Equity Incentive Plan and vested in full on the grant date, making them immediately earned.

Was Jesper Hoeiland’s Allarity Therapeutics (ALLR) equity grant an open-market purchase?

No, the transaction was not an open-market purchase. The Form 4 uses code “A” for a grant, award, or other acquisition, and the footnote clarifies it was a restricted stock unit grant under the company’s equity incentive plan, reflecting compensation.

Did the Allarity Therapeutics (ALLR) RSU grant to Jesper Hoeiland vest immediately?

Yes, the RSU grant vested immediately. The footnote states that the restricted stock units granted pursuant to Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan vested in full on the grant date, meaning there was no multi-year vesting schedule described.

What ownership type is reported for Jesper Hoeiland’s Allarity Therapeutics (ALLR) shares?

The filing classifies his holdings as direct ownership. The transaction record lists the ownership code as “D” and the ownership type as direct, indicating the 25,000 shares following the transaction are held directly by Jesper Hoeiland rather than through an intermediary entity.